TAS-114 is under clinical development by Taiho Pharmaceutical and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TAS-114’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TAS-114 is under development for the treatment of advanced solid tumors including gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, advanced and pancreatic cancer. It is administered orally. The drug candidate is an antimetabolite small molecule inhibitor of deoxyuridine 5'-triphosphate nucleotidehydrolase (dUTPase) and dihydropyrimidine dehydrogenase (DPD). It was also under development for cervical cancer and metastatic non-small cell lung cancer.
Taiho Pharmaceutical overview
Taiho Pharmaceutical (Taiho), a subsidiary of Otsuka Group, develops and markets pharmaceutical products in the field of cancer, allergy, immunology and urology. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor antagonists, antibiotics and medical devices; and consumer health products such as herbal digestive medicine, topical analgesics, antifungal cream and herbal medicine powder, among others. Taiho has production facilities in Tokushima, Saitama, Okayama, Kitajima and Inuyama. It operates through its subsidiaries situated worldwide including Japan, China, Canada, Singapore, the UK and the US. Taiho is headquartered in Tokyo, Japan.
For a complete picture of TAS-114’s drug-specific PTSR and LoA scores, buy the report here.